Erik Danielsen nominated as new board member

Oslo, 23.05.2011 - Erik Danielsen is nominated as new board member in Bionor Pharma ASA.

On the upcoming ordinary general meeting in Bionor Pharma ASA 27(th) May 2011 a
new board member will be elected to replace Henrik Lund, who functioned as board
member until he was appointed CEO from September 1(st) 2010. As candidate for
the new board member, the Nomination committee by Lars Høie (leader), Ivar
Sigurd Eide and Lars Helmer Enger, has nominated Erik Danielsen.
Erik Danielsen is a Norwegian and Swiss citizen. He has an MBA from Universite
de Fribourg and has worked internationally in USA and Europe for more than 20
years. He has worked in Price Waterhouse as auditor, Credit Suisse and Credit
Suisse First Boston as equity strategist and has been CEO in Analitika AS, a
Swiss financial analysis firm. He is currently partner in Bridge Relations Ltd,
a London-based IR services and business consulting firm with special focus on
cleantech and healthcare industry.
Erik Danielsen is specialized in Investor Relations, corporate communications,
financial analysis and business strategy, particularly within the pharmaceutical
industry and biotech sectors. He has extensive contact network to financial
institutions and private investors throughout Europe and North-America, and he
is chairman of the board of the listed ContextVision AB, Sweden, and Analitika
SA, Switzerland.
The other board members of Bionor Pharma ASA, Wenche Rolfsen (chairman), Thomas
Falck (deputy chairman), Elsebeth Budolfsen and Eric Cameron, have one year left
of their election period.